Anaplastic Astrocytoma - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 118 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2016, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.

Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 3, 7 and 7 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 2 molecules, respectively.Anaplastic Astrocytoma.

Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Anaplastic Astrocytoma Overview 8
Therapeutics Development 9
Pipeline Products for Anaplastic Astrocytoma - Overview 9
Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis 10
Anaplastic Astrocytoma - Therapeutics under Development by Companies 11
Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes 12
Anaplastic Astrocytoma - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Anaplastic Astrocytoma - Products under Development by Companies 15
Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes 16
Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 17
AngioChem Inc. 17
Astellas Pharma Inc. 18
Axelar AB 19
Boehringer Ingelheim GmbH 20
Burzynski Research Institute, Inc. 21
Cavion LLC 22
Celldex Therapeutics, Inc. 23
Millennium Pharmaceuticals Inc 24
Novartis AG 25
Orbus Therapeutics, Inc. 26
Pfizer Inc. 27
Tocagen Inc. 28
TVAX Biomedical, Inc. 29
Anaplastic Astrocytoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
afatinib dimaleate - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
alisertib - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Antineoplaston Therapy - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
AXL-1717 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
bendamustine hydrochloride - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
CDX-1401 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Cellular Immunotherapy for Gliomas - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Cellular Immunotherapy for Oncology - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
DNX-2401 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
eflornithine hydrochloride - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
flucytosine + TBio-01 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
flucytosine ER + vocimagene amiretrorepvec - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
irinotecan hydrochloride + TBio-02 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
M-032 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
mibefradil dihydrochloride - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
nilotinib - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
p28 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
paclitaxel trevatide - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
palbociclib - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
TVI-Brain-1 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
Anaplastic Astrocytoma - Dormant Projects 113
Anaplastic Astrocytoma - Discontinued Products 114
Anaplastic Astrocytoma - Product Development Milestones 115
Featured News & Press Releases 115
Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer 115
Dec 07, 2015: Burzynski Research Institute Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1 115
Jun 18, 2015: Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma 116

Appendix 117
Methodology 117
Coverage 117
Secondary Research 117
Primary Research 117
Expert Panel Validation 117
Contact Us 117
Disclaimer 118

List of Tables

Number of Products under Development for Anaplastic Astrocytoma, H2 2016 9
Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Anaplastic Astrocytoma - Pipeline by AngioChem Inc., H2 2016 17
Anaplastic Astrocytoma - Pipeline by Astellas Pharma Inc., H2 2016 18
Anaplastic Astrocytoma - Pipeline by Axelar AB, H2 2016 19
Anaplastic Astrocytoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 20
Anaplastic Astrocytoma - Pipeline by Burzynski Research Institute, Inc., H2 2016 21
Anaplastic Astrocytoma - Pipeline by Cavion LLC, H2 2016 22
Anaplastic Astrocytoma - Pipeline by Celldex Therapeutics, Inc., H2 2016 23
Anaplastic Astrocytoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 24
Anaplastic Astrocytoma - Pipeline by Novartis AG, H2 2016 25
Anaplastic Astrocytoma - Pipeline by Orbus Therapeutics, Inc., H2 2016 26
Anaplastic Astrocytoma - Pipeline by Pfizer Inc., H2 2016 27
Anaplastic Astrocytoma - Pipeline by Tocagen Inc., H2 2016 28
Anaplastic Astrocytoma - Pipeline by TVAX Biomedical, Inc., H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Assessment by Combination Products, H2 2016 31
Number of Products by Stage and Target, H2 2016 33
Number of Products by Stage and Mechanism of Action, H2 2016 35
Number of Products by Stage and Route of Administration, H2 2016 37
Number of Products by Stage and Molecule Type, H2 2016 39
Anaplastic Astrocytoma - Dormant Projects, H2 2016 113
Anaplastic Astrocytoma - Discontinued Products, H2 2016 114